Merck reported a good set of figures, but profitability did not fully match our very optimistic expectations (sales: 0.9%; adjusted EBITDA: -4.1%). Likewise for consensus (sales: +1.3%; adjusted EBITDA: -1.3%). It looks as if pharma was troubled by something temporary but nothing structural. Nevertheless, the company fully delivered towards its guidance.
The strong dividend proposal and the qualitative guidance make us quite optimistic for the current year.
03 Mar 2022
A good ending despite slightly troubled pharma
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
A good ending despite slightly troubled pharma
Merck reported a good set of figures, but profitability did not fully match our very optimistic expectations (sales: 0.9%; adjusted EBITDA: -4.1%). Likewise for consensus (sales: +1.3%; adjusted EBITDA: -1.3%). It looks as if pharma was troubled by something temporary but nothing structural. Nevertheless, the company fully delivered towards its guidance.
The strong dividend proposal and the qualitative guidance make us quite optimistic for the current year.